In contrast to the argument that the inhibition of stimulating oncogenic mutations would be beneficial at all stages of cancer, our model suggests that a restoration of p53/p16/Rb function, while it might be beneficial in very early stages of metastatic development, would not be useful once the smaller cells have been generated. Here, CDKN2A is linked to cancer.